Business
Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders
GAITHERSBURG, Md., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott
About this update from Altimmune, Inc.
[{"type":"text","content":"GAITHERSBURG, Md., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will present body composition data from the Phase 2 MOMENTUM trial of pemvidutide in the treatment of obesity and participate in a panel discussion at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders in Washington, D.C. Details for the panel discussion are as follows: Title:Muscle Wasting in Weight Loss TherapySession:Treatment Approaches to Address Muscle Wasting in the Context of Obesity Therapy & Regulatory IssuesPresenter:Scott Harris, M.D., Chief Medical Officer, Altimmune, Inc.Date/Time:Friday, December 6, 2024 at 9:30 am ET About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com. Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter Company Contact:Greg WeaverChief Financial OfficerPhone: [email protected] Investor Contact:Lee RothBurns McClellanPhone: [email protected] Media Contact:Danielle CanteyInizio Evoke, BiotechPhone: [email protected] This press release was published by a CLEAR® Verified individual. \nSource: Altimmune, Inc","length":6105,"tagName":"div"}]